Home › Compare › SHMSF vs ABBV
SHMSF yields 3478.26% · ABBV yields 3.06%● Live data
📍 SHMSF pulled ahead of the other in Year 1
Combined, SHMSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHMSF + ABBV for your $10,000?
Shimao Services Holdings Limited, an investment holding company, provides property management and community living services in the People's Republic of China. It operates in two segments, Property Management and Related Services; and City Services. The company offers property management services, including security, cleaning, greening and gardening, repair, and maintenance services to construction, gardening, and other property management companies. It also provides community value added services, such as community asset management, carpark asset operation, campus value-added, and retail services; sells hardware devices and software products; and home decoration services, including supply chain services of decoration materials, and marketing and promotion services to property owners and developers, technology companies, and other property management companies. In addition, the company offers value-added services, which comprise display units and property sales venue management, preliminary planning and design consultancy, and repair and maintenance management services to property developers; and city services that include sanitation, cleaning, and sewage and waste treatment. Further, it is involved in the real estate agency, wholesale and retail trading, construction decoration and other construction, education, enterprises management consulting, household management, engineering construction, and hotel management businesses. The company was founded in 2005 and is headquartered in Shanghai, the People's Republic of China. Shimao Services Holdings Limited is a subsidiary of Best Cosmos Limited.
Full SHMSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.